Enfusion (NYSE:ENFN) Hits New 52-Week High – Should You Buy?

Enfusion, Inc. (NYSE:ENFN) hit a new 52-week high during trading on Tuesday . The stock traded as high as $10.78 and last traded at $10.67, with a volume of 16550 shares. The stock had previously closed at $10.62.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus upped their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Enfusion has a consensus rating of “Hold” and an average price target of $10.00.

Enfusion Price Performance

The stock’s fifty day moving average price is $9.64 and its 200-day moving average price is $8.98. The firm has a market cap of $1.38 billion, a PE ratio of 268.82, a price-to-earnings-growth ratio of 3.98 and a beta of 0.97.

Insider Buying and Selling at Enfusion

In related news, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the transaction, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 36.44% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enfusion

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENFN. Barclays PLC increased its position in shares of Enfusion by 251.4% during the 3rd quarter. Barclays PLC now owns 86,039 shares of the company’s stock worth $817,000 after purchasing an additional 61,554 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Enfusion by 7.3% during the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock valued at $9,770,000 after acquiring an additional 70,367 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Enfusion by 6.7% in the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after acquiring an additional 61,032 shares during the period. TenCore Partners LP purchased a new stake in shares of Enfusion in the 3rd quarter valued at approximately $3,938,000. Finally, State Street Corp boosted its position in shares of Enfusion by 2.3% during the 3rd quarter. State Street Corp now owns 952,895 shares of the company’s stock worth $9,043,000 after purchasing an additional 21,729 shares during the period. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.